Study of TU2218 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
This study consists of phase 1b and 2a to evaluate safety, Pharmacokinetics, and efficacy of
TU2218 in combination with Pembrolizumab in patients with advanced solid tumors. The main
purpose of phase 1b is to determine the RP2DC of TU2218 and Pembrolizumab while the main
purpose of phase 2a is to evaluate the antitumor efficacy of TU2218 in combination with
Pembrolizumab in 3 different selected tumor type cohorts.